Cingulate Inc
CING7.700USD
+1.210+18.64%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
46.03MValor de mercado
PerdaP/L TTM
Mais detalhes de Cingulate Inc Empresa
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Informações de Cingulate Inc
Código da empresaCING
Nome da EmpresaCingulate Inc
Data de listagemOct 07, 2021
CEOCallahan (Jennifer L)
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 07
Endereço1901 W. 47Th Place
CidadeKANSAS CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal66205
Telefone19139422300
Sitehttps://www.cingulate.com/
Código da empresaCING
Data de listagemOct 07, 2021
CEOCallahan (Jennifer L)
Executivos da empresa Cingulate Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sex, 6 de fev
Atualizado em: sex, 6 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
2.06%
Werth Family Investment Associates LLC
1.34%
Kestra Advisory Services, LLC
1.28%
Geode Capital Management, L.L.C.
0.58%
UBS Financial Services, Inc.
0.38%
Outro
94.37%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
2.06%
Werth Family Investment Associates LLC
1.34%
Kestra Advisory Services, LLC
1.28%
Geode Capital Management, L.L.C.
0.58%
UBS Financial Services, Inc.
0.38%
Outro
94.37%
Tipos de investidores
Investidores
Proporção
Investment Advisor
4.45%
Corporation
1.38%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.25%
Outro
93.23%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
33
295.34K
5.70%
--
2025Q3
44
295.34K
6.89%
+113.00
2025Q2
41
295.23K
5.36%
+158.62K
2025Q1
38
136.60K
4.92%
-48.84K
2024Q4
38
91.23K
3.95%
+40.70K
2024Q3
38
50.54K
3.01%
-30.23K
2024Q2
36
80.24K
1.97%
+46.92K
2024Q1
36
33.32K
1.85%
+25.60K
2023Q4
33
318.00
10.05%
-5.36K
2023Q3
30
5.68K
6.07%
+3.89K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
73.80K
1.03%
+38.42K
+108.60%
Sep 30, 2025
Werth Family Investment Associates LLC
97.99K
1.36%
--
--
Aug 01, 2025
Kestra Advisory Services, LLC
94.02K
1.31%
+94.02K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
42.41K
0.59%
+10.25K
+31.88%
Sep 30, 2025
UBS Financial Services, Inc.
1.30K
0.02%
-11.35K
-89.74%
Sep 30, 2025
LPL Financial LLC
20.25K
0.28%
+8.07K
+66.32%
Sep 30, 2025
Virtu Americas LLC
10.77K
0.15%
-2.58K
-19.32%
Sep 30, 2025
Quantum Private Wealth, LLC
24.00K
0.33%
+14.00K
+140.00%
Sep 30, 2025
Northern Trust Investments, Inc.
8.00K
0.11%
+8.00K
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Data
Data ex-dividendo
Tipo
Proporção
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
